PhD Scientific Days 2023

Clinical Medicine VI.

Platelet-rich plasma in chronic wound management.

Előadó neve

Dr. Meznerics, Fanni Adél

Neptun code

G68XOW

Előadó munkahelye

Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

Előadó telefonszáma

06304473646

Előadó e-mail címe

f.meznerics@gmail.com

Az előadás címe

Platelet-rich plasma in chronic wound management.

Szerző(k) neve és munkahelye

Fanni Adél Meznerics 1,2, Péter Fehérvári 2, 3, Fanni Dembrovszky 2,4, Kata Dorottya Kovács, Lajos Vince Kemény 1, Dezső Csupor 2,4,5, Péter Hegyi 2,4,6, András Bánvölgyi 1

1. Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
2. Center for Translational Medicine, Semmelweis University, Budapest, Hungary
3. Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary
4. Institute for Translational Medicine, Medical School, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
5. Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary
6. Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University,
Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Clinical Medicine VI.

Language of the presentation

English

Preferred session

Clinical Medicine

Összefoglaló szövege

Introduction: Chronic wounds place a heavy burden on the healthcare system as the cost of wound management is estimated to account for 5.5% of all healthcare expenditures.
Aims: Our aim was to investigate the therapeutic effects of platelet-rich plasma on the treatment of chronic wounds.
Method: Our systematic review and meta-analysis are reported according to the PRISMA 2020 Statement. The systematic literature search was performed in four databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, and Web of Science, from inception to 29th October, 2021. The review protocol was registered on PROSPERO under registration number CRD42021287881. Randomized clinical trials reporting on patients with chronic wounds treated with platelet-rich plasma were included, comparing platelet-rich plasma (intervention) with conventional ulcer therapy (control). Two authors independently extracted relevant data into a pre-defined data sheet, and a third reviewer resolved discrepancies between the two authors. We pooled data using the random effects model. Our primary outcome was the change in wound size; secondary outcomes were healing time, infection, pain, adverse events, amputation, recurrence, and quality of life.
Results: Our systematic search provided a total of 2,688 articles, and we identified 48 eligible studies after selection and citation search. Thirty-three study groups of 29 RCTs with a total of 2,198 wounds showed that the odds for complete closure were significantly higher in the PRP group than in the control group (OR=5.32; CI: 3.37; 8.40; I2=58%), whereas pooled standardized mean differences from 16 studies showed a significant difference between the post-treatment wound size of the intervention and the control groups (SMD = -1.21, CI: -1.74; -0.65; I2 = 92.5%), the PRP group showing greater improvement.
Conclusions: Platelet-rich plasma is a safe and effective modality to enhance wound healing. By implementing it in clinical practice, platelet-rich plasma could become a widely used, valuable tool as it could not only improve patients’ quality of life but also decrease the healthcare burden of wound management.
Funding: The research was supported by Semmelweis 250+ Excellence Scholarship.

University and Doctoral School

Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine

Supervisor

András Bánvölgyi MD., PhD

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6804

Start

09:30

End

09:45

Authors (legacy)

Fanni Adél Meznerics 1,2, Péter Fehérvári 2, 3, Fanni Dembrovszky 2,4, Kata Dorottya Kovács, Lajos Vince Kemény 1, Dezső Csupor 2,4,5, Péter Hegyi 2,4,6, András Bánvölgyi 1

1. Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
2. Center for Translational Medicine, Semmelweis University, Budapest, Hungary
3. Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary
4. Institute for Translational Medicine, Medical School, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
5. Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary
6. Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University,
Budapest, Hungary